Sagimet Biosciences (SGMT) Expected to Announce Earnings on Thursday

Sagimet Biosciences (NASDAQ:SGMT) is expected to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.3709) per share for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last announced its earnings results on Wednesday, March 11th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. On average, analysts expect Sagimet Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sagimet Biosciences Stock Up 8.5%

SGMT opened at $8.38 on Thursday. The business has a fifty day moving average of $5.80 and a 200 day moving average of $6.28. Sagimet Biosciences has a 52-week low of $3.08 and a 52-week high of $11.41. The stock has a market cap of $273.02 million, a P/E ratio of -5.34 and a beta of 3.60.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Guggenheim dropped their price objective on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Oppenheimer restated an “outperform” rating on shares of Sagimet Biosciences in a report on Friday, May 1st. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Sagimet Biosciences in a report on Wednesday, March 11th. Canaccord Genuity Group boosted their price objective on Sagimet Biosciences from $28.00 to $49.00 and gave the company a “buy” rating in a report on Monday. Finally, Rodman & Renshaw assumed coverage on Sagimet Biosciences in a report on Thursday, March 26th. They set a “buy” rating and a $28.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.63.

Trending Headlines about Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 quarter and full‑year EPS estimates and materially increased long‑range forecasts (FY2027–FY2030), while maintaining a Buy rating and a $29 price target — a clear analyst catalyst that can drive investor demand. HC Wainwright raises estimates, Buy $29 target
• Positive Sentiment: A Zacks piece highlights that the mean of analysts’ price targets implies ~241.8% upside from current levels, drawing attention to significant upside implied by street estimates — this can attract speculative and momentum investors. Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
• Positive Sentiment: Zacks also ran a momentum‑style piece framing SGMT as a strong momentum stock — coverage like this can amplify buying interest from traders focused on short‑term strength. Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
• Neutral Sentiment: Near‑term fundamentals remain a constraint: consensus still shows negative EPS for FY2026 (around -$1.48 to -$1.51), so the story is driven by future profitability expectations and pipeline/strategy execution rather than current earnings. Recent quarterly results (March quarter) did beat estimates, which supports the bullish narrative but doesn’t eliminate short‑term reported losses. MarketBeat Sagimet overview

Insider Buying and Selling at Sagimet Biosciences

In other Sagimet Biosciences news, CEO David Happel sold 12,101 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total value of $64,861.36. Following the completion of the sale, the chief executive officer directly owned 677,621 shares in the company, valued at approximately $3,632,048.56. This represents a 1.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 14.70% of the company’s stock.

Institutional Investors Weigh In On Sagimet Biosciences

Several hedge funds have recently made changes to their positions in SGMT. Royal Bank of Canada lifted its holdings in shares of Sagimet Biosciences by 819.2% in the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock worth $29,000 after buying an additional 4,391 shares during the period. Virtu Financial LLC purchased a new stake in shares of Sagimet Biosciences in the 4th quarter worth $62,000. Bank of America Corp DE lifted its holdings in shares of Sagimet Biosciences by 81.8% in the 2nd quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock worth $76,000 after buying an additional 4,473 shares during the period. Jefferies Financial Group Inc. purchased a new stake in shares of Sagimet Biosciences in the 3rd quarter worth $95,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Sagimet Biosciences in the 1st quarter worth $105,000. 87.86% of the stock is currently owned by hedge funds and other institutional investors.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.